Literature DB >> 6601716

Lymphocyte subsets in Sjogren's syndrome: a quantitative analysis using monoclonal antibodies and the fluorescence-activated cell sorter.

A Bakhshi, N Miyasaka, P Kavathas, T E Daniels, C V Strand, L A Herzenberg, N Talal.   

Abstract

Lymphocyte subsets in the peripheral blood of 18 patients with Sjogren's syndrome (SS) were studied using monoclonal antibodies and the fluorescence-activated cell sorter (FACS). The percentage of T cells was decreased when compared to normal controls. In primary SS, there was a proportional decrease in both suppressor/cytotoxic (anti-Leu-2a reactive) and helper/inducer (anti-Leu-3a reactive) T cells with an unchanged helper/suppressor ratio (1.8 vs. 1.7 for normals). In SS with an associated connective tissue disorder, there was a significant decrease only in the suppressor/cytotoxic subset. There was increase in B cells and null cells in primary SS compared to controls. Quantitative immunofluorescence allowed the calculation of determinant density per cell. Cells expressing low antigen density Leu-2a were increased in 8 patients (4 with primary SS and 4 with SS with an associated disorder). Thus, in addition to quantitative changes in lymphocyte subsets, we found changes in Leu-2a expression suggesting abnormal differentiation of the suppressor/cytotoxic subset. These changes may contribute to the immunoregulatory disturbance in Sjogren's syndrome.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6601716

Source DB:  PubMed          Journal:  J Clin Lab Immunol        ISSN: 0141-2760


  2 in total

Review 1.  Could Lymphocyte Profiling be Useful to Diagnose Systemic Autoimmune Diseases?

Authors:  Guillermo Carvajal Alegria; Pierre Gazeau; Sophie Hillion; Claire I Daïen; Divi Y K Cornec
Journal:  Clin Rev Allergy Immunol       Date:  2017-10       Impact factor: 8.667

2.  T-lymphocyte populations in normal and coeliac small intestinal mucosa defined by monoclonal antibodies.

Authors:  D Jenkins; A Goodall; B B Scott
Journal:  Gut       Date:  1986-11       Impact factor: 23.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.